[On Demand]
MultiplexDX is one of the most innovative biotech corporations, created to bring revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets.

The mission of MultiplexDX is to eliminate cancer misdiagnosis by creating reliable, 100% accurate, quantitative and affordable diagnostic tests. MDX’s IP-based solutions combine visualization and sequencing technologies to quantify 7 or more cancer markers to give each diagnosis a specific “barcode,” which will indicate not only the cancer type but also the duration of personalized treatment for that cancer. As our name suggests, we also use multiplexing; cross-testing and verifying the same result from at least two independent sources.

MultiplexDX IP-based platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technology.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Slovakia(Slovak Republic)
Year Founded:
Main Therapeutic Focus:
Lead Product in Development:
Multiplex8+ (Breast Cancer Diagnostics)
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Director of Research and Development